Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia

Thoas Fioretos, Per-Gunnar Nilsson, P Åman, Sverre Heim, Ulf Kristoffersson, C Malm, B Simonsson, Ingemar Turesson, Felix Mitelman

Research output: Contribution to journalArticlepeer-review


We have analyzed the M-bcr breakpoint position in 133 Philadelphia-positive chronic myeloid leukemia patients and correlated the findings with clinical, hematologic, and cytogenetic data. We also investigated the splicing pattern of the BCR-ABL mRNA in 30 patients, using reverse transcriptase PCR. No statistically significant differences were found between breakpoint position within M-bcr and clinical parameters at diagnosis, the karyotypic evolution pattern, or the leukemic phenotype during blast crisis. Furthermore, the breakpoint position within M-bcr did not correlate with the duration of chronic phase or survival time. When the splicing pattern of the BCR-ABL mRNA was compared with the results of the genomic breakpoint mapping, it was found that approximately 60% (8/14) of the patients with a 5' break expressed b2a2 fusion mRNA, whereas all patients (10/10) with a 3' break expressed b3a2 BCR-ABL mRNA.
Original languageEnglish
Pages (from-to)1225-1231
Issue number8
Publication statusPublished - 1993

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200), Division of Hematology and Transfusion Medicine (013041100), Division of Clinical Genetics (013022003)

Subject classification (UKÄ)

  • Cancer and Oncology


Dive into the research topics of 'Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia'. Together they form a unique fingerprint.

Cite this